Following Priority Review, Dupixent is now available to patients as young as 12 yearswith inadequately controlled CRSwNP ...

Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity ...

Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in ...

ROCKVILLE, MD, USA I 15, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and ...

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I 13, 2024 I Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab ...

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus ...

WILMINGTON, DE, USA I 14, 2024 I Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential ...

NEW YORK, NY, USA I September 14, 2024 I Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against ...

NEW YORK, NY, USA I 13, 2024 I OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody ...

SUZHOU, China I 13, 2024 I MediLink Therapeutics (MediLink) today presented clinical data for YL201, a novel B7H3-targeting antibody drug conjugate ...

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease ...